Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Safety outcomes and major postoperative complications were similar between both groups
In a head-to-head trial against semaglutide (the SURPASS-2 trial), tirzepatide produced significantly greater weight loss, with participants taking the highest dose of tirzepatide losing an average of 11.2 kg (24.7 lbs), compared to 5.7 kg (12.5 lbs) for those taking semaglutide 1 mg
Maternal supply of methionine during late-pregnancy enhances rate of Holstein calf development in utero and postnatal growth to a greater extent than colostrum source
TRIUMPH-3 and the Cardiovascular Data (Where I Need to Correct Myself) In June I wrote that TRIUMPH-3 was critical because cardiovascular outcomes data will likely be required for full regulatory approval. I was half right, and I want to fix that in public
![Howling Mine [International Collectors' Edition] UPR009](https://cdn.shopify.com/s/files/1/0794/9162/9342/files/b631cff1-6f5f-41af-ada2-46e8eefe6849.png?v=1773389420)
